

APPLICANTS: Moutsatos I. et al.  
SERIAL NO.: 09/148,234  
FILED: September 4, 1998  
PAGE: 3 of 4

28. (Previously Amended) The method of claim 24, wherein said mesenchymal stem cell expresses parathyroid hormone and a parathyroid hormone receptor protein.

#### **REMARKS**

Claims 24-28 are pending in the Subject Application. Claims 11, 12, 14-17 and 19-23 have been previously cancelled, and claim 24 has been amended. Support for the claims, is found *inter alia* in the specification and examples herein, for example, in the specification at page 2 lines 28-31 and page 28, lines 20-31. None of the amendments made herein constitute the addition of new matter.

#### **REJECTION UNDER 35 U.S.C. 112:**

In the Office Action, the Examiner provided a new rejection for claims 24-29 under 35 U.S.C. 112, as allegedly containing subject matter which does not reasonably convey to one skilled in the art that the inventor at the time the Application was filed was in possession of the invention. In particular, the rejection was based on claims directed to mesenchymal stem cells.

Applicants respectfully disagree. Example 11 of the subject Application clearly demonstrates the successful use of ex-vivo C3H10T1/2 cells transformed/transduced with BMP-2, for implantation at a site of a bone infirmity, resulting in the formation of enhanced, organized, functional, bone formation at the defect site, in particular along the defect edges. Applicants maintain that one skilled in the art would know and understand that C3H10T1/2 cells are representative of mesenchymal stem cells, and Applicants submit (Appendix 1 and 2) the following references to support that such knowledge was in possession of one skilled in the art, at the time of the filing of the Application:

1) Nakamura T, Aikawa T, Iwamoto-Enomoto M, Iwamoto M, Higuchi Y, Pacifici M, Kinto N, Yamaguchi A, Noji S, Kurisu K, Matsuya T, Maurizio P. Induction of osteogenic differentiation by hedgehog proteins. *Biochem Biophys Res Commun.* 1997 Aug 18; 237(2):465-9.

2) Ahrens M, Ankenbauer T, Schroder D, Hollnagel A, Mayer H, Gross G. Expression of human bone morphogenetic proteins-2 or -4 in murine mesenchymal progenitor C3H10T1/2 cells induces differentiation into

APPLICANTS: Moutsatos I. et al.  
SERIAL NO.: 09/148,234  
FILED: September 4, 1998  
PAGE: 4 of 4

distinct mesenchymal cell lineages. DNA Cell Biol. 1993 Dec;  
12(10):871-80.

Thus, contrary to the Examiner's assertion, there is support in the specification as filed for the term "mesenchymal stem cell"

### **REJECTION UNDER 35 U.S.C. § 103:**

In the Office Action, the Examiner rejected claims 24-26 under 35 U.S.C. § 103 as allegedly being unpatentable over Ahrens et al, in view of US Patent No. 5,763,416 and US Patent No. 6,048,964. The Examiner asserted that based on Ahrens et al, in view of US Patent No. 5,763,416 and US Patent No. 6,048,964, it would have allegedly been obvious to one of ordinary skill in the art to combine to make the claimed invention, that of preparing ex-vivo cultured stem cells transformed with BMP-2 for implantation at a site of a bone infirmity.

In response, Applicants traverse the rejection of claims 24-26 under 35 U.S.C. § 103. Applicants maintain that Ahrens et al, in view of US Patent No. 5,763,416 and US Patent No. 6,048,964, do not render the claimed invention obvious, nor would a person of ordinary skill in the art have had a reasonable and/or credible expectation of success in obtaining the instant claimed invention given the teachings of Ahrens et al, in view of US Patent No. 5,763,416 and US Patent No. 6,048,964. The Examiner has alleged that Bonadio discloses the use of bone progenitor cells transformed with a BMP for stimulating bone formation.

Applicants respectfully disagree. Applicants maintain that although Bonadio suggest the use of bone progenitor cells for stimulating bone formation, such a suggestion is merely speculative and not credible, in view of what Bonadio demonstrated, and the knowledge in the art at the time.

Bonadio demonstrates **only** direct gene transfer of a bone morphogenetic protein. Bondaio asserts that the constructs are targeted to progenitor cells, however, there is no

APPLICANTS: Moutsatos I. et al.  
SERIAL NO.: 09/148,234  
FILED: September 4, 1998  
PAGE: 5 of 4

credible support for such a contention, **nor is it likely** that direct transfer of a nucleic acid to a site of bone infirmity is **appreciably** taken up *in situ* by a bone progenitor cell. Applicants submit in a Declaration herein that Bonadio **describes** the use of an adenoviral vector for gene transfer experiments for *in vivo* bone regeneration, however adenoviral vector uptake is mediated by the CAR receptor, whose expression has been shown to be drastically diminished, if not absent in hematopoietic progenitor cells, as compared to their differentiated counterparts. Hematopoietic progenitor cells in fact, are more differentiated than mesenchymal stem cells, and therefore it is unlikely that an even less differentiated cell type will exhibit appreciable CAR expression. The Rebel et al article, as described in the Declaration, further indicates that gene transfer does not appreciably occur in cells, which have diminished CAR expression. Thus, in the absence of a demonstration to the contrary, one skilled in the art, would assume, based on the foregoing, that adenoviral transfer of a gene would not be successful in progenitor cells *in situ*.

Bonadio further describes the use of DNA-soaked sponges as another means of gene delivery, wherein the DNA is purportedly taken up by progenitor cells. Applicants submit additional articles, as described in the attached Declaration, indicating that less differentiated cells have less propensity toward DNA uptake, similar to adenoviral uptake, and therefore neither method described by Bonadio provides for appreciable uptake of a foreign DNA sequence by mesenchymal stem cells. Thus, one skilled in the art would not credibly believe that Bonadio could predict uptake of a construct *in situ* by progenitor or stem cells.

Further, the Examiner has alleged that the motivation to combine the Bonadio and Ahrens references need only take into account a reasonable expectation of success in treating a site of bone infirmity in a human through the use of cultured mesenchymal stem cells that overexpress BMP-2, and the fact that Applicants data demonstrates the presence of autocrine and paracrine effects such cells demonstrates the fact that these mechanisms are necessarily present. Applicants respectfully disagree. Applicants maintain that there is no motivation to combine these references with a reasonable expectation of success for inducing enhanced, organized, functional bone formation **at a site of bone infirmity** in a human.

APPLICANTS: Moutsatos I. et al.  
SERIAL NO.: 09/148,234  
FILED: September 4, 1998  
PAGE: 6 of 4

Though Bonadio describes that progenitor cells are targeted by his gene transfer methods, such a conclusion is not credible, in lieu of direct demonstration by Bonadio that such is the case, as much of the cell population targeted is not a stem or progenitor cell, moreover, uptake of the DNA by such cells *in situ*, according to one skilled in the art is drastically reduced, such that Bonadio does not credibly provide a foundation that BMP gene transfer provides more than paracrine effects for healing a bone infirmity.

While Ahrens provides for in vitro responses of progenitor cells to **a group of osteoinductive compounds**, which include *inter-alia*, a BMP, Ahrens provides no basis for the likelihood that implantation of such cells, transduced only with a BMP-2 vector, *in vivo* will stimulate bone induction **at a site of bone infirmity**. Such a result is predicated on appropriate cell homing and orientation along the defect edges, a result which could not have been foreseen, based on either Ahrens, or credibly considered, in view of Bonadio. Moreover, the combination of Bonadio and Ahrens could not have predicted the unexpected results of the claimed invention, the formation of enhanced, organized, functional bone formation evidenced in the instant invention, nor do they render obvious the likelihood of such formation at a site of bone infirmity.

Further, Ahrens demonstrates differentiation of MSCs in vitro, and in fact, as described in the Declaration attached hereto (Appendix 3), mesenchymal stem cells, which are cultured and differentiated *in vitro* when implanted *in vivo*, do not form functional tissue, and lose their cell surface marker phenotype (De Bari C. et al., Arthritis Rheum. 2004 Jan; 50(1):142-50). Thus, in view of the art cited, Ahrens in combination with Bonadio do not credibly suggest that an ex-vivo cultured, BMP-2 transduced/transformed mesenchymal stem cell will form enhanced, organized, functional bone at a site of bone infirmity following implantation.

Applicants maintain that the presence of autocrine and paracrine effects of expressed bone morphogenesis protein 2 resulted in the enhanced, organized, functional bone formation **at the site of bone infirmity**. Applicants maintain that it would not be obvious to combine the teachings of Bonadio, which only credibly describes paracrine effects of BMP on bone formation alone, and Ahrens, which demonstrates autocrine effects of **a group of**

APPLICANTS: Moutsatos I. et al.  
SERIAL NO.: 09/148,234  
FILED: September 4, 1998  
PAGE: 7 of 4

**osteoinductive compounds** to arrive at enhanced, organized, functional bone formation at a site of bone infirmity. Applicants maintain that combining the references of Bonadio and Ahrens do not credibly suggest cultured, progenitor cells transformed/transduced with a BMP-2 alone, would effectively form bone at a site of infirmity, much less, that such bone formed would be enhanced, and organized along defect edges, and providing functional bone, which could only be revealed by the claimed invention.

Moreover, Applicant's unexpectedly discovered that ex-vivo cultured mesenchymal stem cells transduced/transformed with BMP such as BMP-2 form greater amounts of bone, than what is achieved by direct gene transfer, the presence of the protein, or differentiated cells secreting BMP-2, and that the bone formation is oriented along defect edges. Applicants results demonstrate bone formation, qualitatively and quantitatively, via the implantation of ex-vivo cultured, BMP-2 transduced/transformed mesenchymal stem cells, at a site of bone infirmity. Thus, a method of inducing enhanced (as exemplified in the subject Application in Example 11, by greater amounts of bone formed), organized (as exemplified in the subject Application in Example 11, by orientation of the bone formation along defect edges), functional bone formation at a site of bone infirmity, is novel and unobvious in view of the art.

In addition, the Examiner has also rejected claim 27 in view of the above cited references, further in view of Wozney (ref?), under 35 USC 103.

Wozney teaches the utility of expressing a BMP receptor for BMP-2 in cells responding to the growth factor. Applicants maintain, by reasoning disclosed hereinabove, that the previously cited references do not render obvious the methods of inducing functional bone formation via implanting ex-vivo cultured MSC transfected with BMP-2. Since the methods are not obvious in view of the art, neither is MSC expression of a BMP-2 receptor. Therefore, Applicants submit that the additional reference does not render the instant invention obvious.

APPLICANTS: Moutsatos I. et al.  
SERIAL NO.: 09/148,234  
FILED: September 4, 1998  
PAGE: 8 of 4


further in view of Hattersley, under 35 USC 103. Hattersley teaches the use of PTH and its receptor in the context of BMP-2. Applicants similarly maintain, by reasoning disclosed hereinabove, that the previously cited references do not render obvious the methods of inducing functional bone formation via implanting ex-vivo cultured MSC transfected with BMP-2. Since the methods are not obvious in view of the art, neither is MSC expression of a PTH/PTH receptor. Therefore, Applicants submit that the additional reference does not render the instant invention obvious.

Accordingly, Applicants request the Examiner to reconsider and withdraw the rejection of the claims under 35 U.S.C. 103.

Based on the foregoing, the pending claims are deemed to be allowable. Their favorable reconsideration and allowance is respectfully requested. Should the Examiner have any question or comment as to the form, content or entry of this Amendment, the Examiner is requested to contact the undersigned at the telephone number below.

The undersigned Attorney hereby authorizes the United States Patent and Trademark Office to charge Deposit Account No. 05-0649 for any fees required.

Respectfully Submitted,



Mark S. Cohen  
Registration No. 42,425  
Attorney for Applicants

Date: September 26, 2004

Eitan, Pearl, Latzer & Cohen Zedek, LLP  
Rockefeller Plaza, Suite 1001  
New York, NY 10020  
Telephone: 212 632 3494  
Facsimile: 212 632 3490